| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | 17-AAG | GDSC1000 | pan-cancer | AAC | -0.16 | 5e-07 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | -0.17 | 5e-06 |
| mRNA | navitoclax:sorafenib (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.16 | 6e-06 |
| mRNA | RO-3306 | GDSC1000 | pan-cancer | AAC | -0.16 | 8e-06 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | -0.13 | 8e-05 |
| mRNA | PD-0332991 | GDSC1000 | pan-cancer | AAC | -0.14 | 9e-05 |
| mRNA | 17-AAG | CCLE | pan-cancer | AAC | -0.19 | 0.0001 |
| mRNA | AUY922 | GDSC1000 | pan-cancer | AAC | -0.13 | 0.0002 |
| mRNA | AZD0530 | CTRPv2 | pan-cancer | AAC | -0.13 | 0.0002 |
| mRNA | BRD-K94991378 | CTRPv2 | pan-cancer | AAC | 0.15 | 0.0003 |